SRZN · Surrozen, Inc./DE
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $11.51M | $3.48M | $10.66M | $0 | $12.5M | $0 | — | |
| $34.58M | $29.37M | $21.13M | $27.23M | $37.01M | $40.18M | $25.68M | |
| $21.28M | $16.2M | $15.06M | $15.8M | $19.83M | $14.21M | $7.12M | |
| $222K | $537K | $1.44M | $1.91M | $1.96M | $2.07M | $1.94M | |
| — | — | — | $2.75M | — | — | — | |
| $55.86M | $45.57M | $36.19M | $45.78M | $56.84M | $54.39M | $32.81M | |
| -$44.35M | -$42.09M | -$25.54M | -$45.78M | -$44.34M | -$54.39M | -$32.81M | |
| — | -1210.58% | -239.69% | — | -354.71% | — | — | |
| -$44.13M | -$41.56M | -$24.1M | -$43.87M | -$42.38M | -$52.33M | -$30.87M | |
| $3.55M | $3.02M | $1.69M | $2.34M | $781K | $72K | $91K | |
| -$101.26M | -$26.31M | -$19.32M | $398K | $7.55M | -$329K | $0 | |
| — | -$242.03M | -$63.56M | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$332.13M | -$242.03M | -$63.56M | -$43.04M | -$36M | -$54.65M | -$32.72M | |
| — | -6960.77% | -596.56% | — | -288.03% | — | — | |
| — | — | -$63.56M | -$42.8M | -$36.13M | -$54.77M | -$32.72M | |
| USD/shares | -$36.39 | -$32.37 | -$21.67 | -$21.33 | -$15.56 | -$33.15 | — |
| USD/shares | -$39.55 | -$32.37 | -$21.67 | -$21.33 | -$15.56 | -$33.15 | — |
| shares | — | 7478 | 2933 | 2018 | 2314 | 1645.9333 | 1.06M |
| shares | — | 7478 | 2933 | 2018 | 2314 | 1645.9333 | 1.06M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $2.61M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 307 similar-size Biotechnology companies (of 514 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 |
|---|---|---|
| United States | $3,500,000 | $700,000 |
| Germany | — | $10,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research Service Revenue | $3,477,000 | $655,000 | $0 |
| Collaboration and License Revenue | $0 | $10,000,000 | $0 |